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The susceptibility of drug-resistant hepatitis B virus (HBV) mutants to lamivudine, 2 
adefovir, tenofovir, entecavir and 2,4-diamino-6-[2-(phosphonomethoxyethoxy]pyrimidine 3 
(PMEO-DAPym), a novel acyclic pyrimidine analogue, was assessed in vitro. Most drug-4 
resistant mutants, including multidrug resistant strains, remained sensitive to tenofovir and 5 
PMEO-DAPym. Therefore, the latter molecule deserves further evaluation for the treatment 6 





















Treatment of chronic hepatitis B virus (HBV) infection requires long term administration with 1 
nucleos(t)ide analogs [lamivudine [(-)-β-L-2’,3’-dideoxy-3’ thiacytidine]), adefovir dipivoxil 2 
(9-[(2-phosphonylmethoxy)ethyl]adenine), entecavir (2-amino-1,9-dihydro-9-[(1S, 3R, 4S)-4-3 
hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one, monohydrate) or 4 
telbivudine (β-l-2′-deoxythymidine)] (28). However, this leads to the emergence of HBV 5 
strains harbouring mutations within the reverse transciptase (RT) sequence that confer 6 
resistance to these drugs (14, 28, 29). The incidence of resistance increases progressively each 7 
year, reaching 70 % after 4 years of lamivudine and 29% after 5 years of adefovir dipivoxil 8 
therapy (9, 14). Currently, there are two options to treat patients who carry lamivudine-9 
resistant mutants. Lamivudine can be switched to adefovir-dipivoxil or entecavir with the risk, 10 
however, of developing adefovir-resistance (7, 8) or entecavir-resistance (4, 19) in the long-11 
term. Adefovir dipivoxil can also be added to ongoing lamivudine monotherapy (7, 8)  to 12 
delay further resistance, as both drugs have a favorable cross-resistance profile when used in 13 
combination (1, 22, 29). However, the emergence of HBV strains harbouring simultaneously 14 
lamivudine- and adefovir-resistance mutations was recently reported within the viral 15 
quasispecies of a patient who successively failed lamivudine and lamivudine plus adefovir 16 
dipivoxil add-on therapy (24). The HBV resistant mutants that are selected after successive 17 
failure to lamivudine and entecavir are resistant to both drugs (20, 23, 26). Thus, the 18 
development of novel HBV inhibitors is needed to overcome HBV drug resistance, and to 19 
design new combination strategies to delay or prevent drug resistance. Different nucleoside 20 
analogs are currently in development. Recently, 2,4-diamino-6-[(2-21 
phosphonomethoxy)ethoxy]pyrimidine (PMEO-DAPym), an acyclic pyrimidine nucleoside 22 
analog phosphonate, was shown to inhibit in vitro human immunodeficiency virus (HIV) and 23 
HBV replication with a potency comparable to that of  adefovir and tenofovir [(R)-9-[(2-24 
phosphonylmethoxy)propyl]adenine] (2, 11, 27). Tenofovir has been approved for HIV 25 
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therapy and is in phase III trial for HBV infection (25). Moreover, PMEO-DAPym proved to 1 
have equipotent activity against wild-type (wt) and lamivudine-resistant rtM204V mutant 2 
HBV in inducible transfected hepatoma cell lines (27). In the present study, we investigated, 3 
in transiently transfected Huh7 cells, the cross-resistance profiles of a series of drug-resistant 4 
HBV mutants, including multiple drug-resistant strains, to PMEO-DAPym and this in direct 5 
comparison with other drugs in parallel assays. 6 
First, we determined the effect of the compounds on Huh7 cell viability by 7 
determining the concentration of drug that reduced the uptake of neutral red dye by 50 % 8 
(CC50), as described before (10). Transient transfection of Huh7 cells was then performed as 9 
previously described with plasmids containing 1.1 genome unit of wt or mutant HBV strain 10 
under the control of the chicken beta actin promoter (6). One group of constructs contained 11 
the genome of HBV laboratory strains (genotype D, serotype ayw) including wt and resistant 12 
HBV mutants obtained by site directed mutagenesis (lamivudine-resistant: rtL180M/M204V; 13 
adefovir-resistant: rtN236T; lamivudine+adefovir-resistant: rtL180M/M204V/N236T) (3, 6, 14 
17). The second group of constructs contained HBV genomes cloned from the viral 15 
quasispecies of two HBV chronically infected patients who failed sequential therapy with 16 
currently approved HBV inhibitors (23, 24). The following clinical isolates (cloned HBV 17 
genomes) were studied: lamivudine-resistant mutants: rtL180M/M204V, rtL180M/A181V, 18 
rtV173L/L180M/M204V; lamivudine+adefovir-resistant mutants: rtV173L/L180M/A181V, 19 
rtV173L/L180M/A181V/M204V, rtV173L/L180M/A181V/M204V/N236T, 20 
rtV173L/L180M/A181V/N236T; entecavir-resistant mutant: rtL180M/S202G/M204V. 21 
Antiviral assays using transfected cells, purification of intracellular HBV DNA and its 22 
analysis by southern blotting were performed as previously described (3, 6). 23 
As shown in Table 1, in Huh7 cells, PMEO-DAPym had little or no effect on cell 24 
viability [CC50 > 1,000 µM], as was also the case for lamivudine and tenofovir. The CC50 25 
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value for entecavir and adefovir were 125 ± 35 µM and 365 ± 120 µM, respectively. 1 
Furthermore, PMEO-DAPym had no effect on HBsAg production by WT HBV transfected 2 
cells (data not shown). When the anti-HBV activity was assessed, entecavir proved to be the 3 
most potent compound with the lowest 50% effective concentration (EC50), followed by 4 
lamivudine, PMEO-DAPym, adefovir and tenofovir. The EC50 of PMEO-DAPym was 3 to 4-5 
fold lower than that of adefovir and tenofovir, under our in vitro conditions (Table 1). The 6 
EC50 of PMEO-DAPym was higher under our in vitro conditions using Huh7 cells by 7 
comparison with the results obtained in a stable cell line derived from HepG2 cells (27). This 8 
type of EC50 variations between Huh7 and HepG2 cells has already been observed previously 9 
with other nucleoside analogs (17); however the ranking of antiviral potency was not affected. 10 
This may indicate that the intracellular metabolism including entry, transport, 11 
phosphorylation, and pumping out of this nucleoside analogs may depend on the cell lines 12 
used for the experiment. 13 
 PMEO-DAPym inhibited the replication of both laboratory and clinical lamivudine-14 
resistant HBV variants, rtL180M/M204V and rtV173L/L180M/M204V strains, as efficiently 15 
as wt HBV (Tables 2, 3). The rtL180M/A181V mutant displayed a 4.8-fold decreased 16 
susceptibility to PMEO-DAPym. However, among the drugs studied, tenofovir was the only 17 
one which inhibited this mutant as well as wt HBV (Table 3). Lamivudine-resistant HBV 18 
strains show decreased susceptibility to entecavir as compared with wild-type HBV strains 19 
(Tables 2, 3). Interestingly, the laboratory HBV strain rtL180M/M204V engeneered by site 20 
directed mutagenesis (Table 2) is more susceptible to entecavir than its counterpart derived 21 
from one patient (Table 3). Discrepancies between the susceptibility to entecavir of 22 
laboratory- or patient- derived HBV rtL180M/M204V strains were already observed (20), and 23 
may be explained by differences in the genetic background of the strains outside of the 24 
polymerase region that has been cloned. 25 
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As previously reported, the rtN236T mutation identified in patients who failed 1 
adefovir dipivoxil therapy decreased the sensitivity to adefovir by 3.2 to 7.3 (1, 3, 22) and to 2 
tenofovir by 4.5-fold (3) (Table 2). The rtL180M/S202G/M204V mutant, identified in a 3 
patient who failed successively lamivudine and entecavir therapy (23), displayed a 210-fold 4 
resistance to entecavir and a >100-fold resistance to lamivudine (Table 3). Interestingly, both 5 
adefovir- and entecavir-resistant HBV strains were sensitive to PMEO-DAPym (Tables 2, 3)  6 
All four lamivudine+adefovir-resistant mutants, characterized in a patient who failed 7 
sequential therapy, displayed a 2.1 to 5.1-fold decreased susceptibility to PMEO-DAPym 8 
depending on the combination of mutations they harboured (Table 3). The EC50 of PMEO-9 
DAPym for mutants rtV173L/L180M/A181V, rtV173L/L180M/A181V/M204V and 10 
rtV173L/L180M/A181V/M204V/N236T was lower than that of tenofovir and similar for 11 
mutant rtV173L/L180M/A181V/N236T. However, the resistance factor observed for all four 12 
lamivudine+adefovir-resistant mutants was slightly higher for PMEO-DAPym
 
as compared to 13 
tenofovir. PMEO-DAPym
 
and tenofovir had a greater inhibitory activity on these multiple  14 
drug-resistant mutants than lamivudine and entecavir; adefovir had slightly higher resistance 15 
factors for these mutants but its in vivo pharmacological characteristics preclude its use at 16 
higher dosage (15). The inhibitory activity of the evaluated compounds against the 17 
rtV173L/L180M/A181V/N236T mutant (lamivudine and adefovir escape mutant) was ranged 18 
in the following order of potency: tenofovir > PMEO-DAPym
 
> entecavir > adefovir > 19 
lamivudine.  20 
Our results provide direct information regarding the cross-resistance profile of the 21 
lamivudine-, lamivudine+adefovir- and entecavir-resistant HBV strains isolated from patients 22 
who failed sequential therapy. Noteworthy, entecavir may not represent the best anti-HBV 23 
agent to treat patients who failed a lamivudine therapy, as lamivudine may lead to the 24 
emergence of HBV variants harbouring rtL180M/M204V or rtL180M/A181V mutations that 25 
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impair the antiviral effect of entecavir (Tables 2 and 3). Moreover, long-term entecavir 1 
treatment of patients infected with lamivudine resistant HBV strains leads to the selection of 2 
secondary mutations that, on a genetic background of lamivudine-resistant mutations, confer 3 
increased resistance to entecavir (20, 23). Nevertheless, entecavir may be valuable for the 4 
treatment of patients who failed adefovir dipivoxil therapy since mutants harbouring the 5 
rtN236T mutation, in absence of the lamivudine-resistant mutation rtM204V,  retained 6 
susceptibility to entecavir (Tables 2 and 3) (3). Tenofovir displayed an antiviral activity 7 
against wt HBV similar to adefovir (Table 1), and efficiently inhibited the replication of a 8 
series of lamivudine-, adefovir-, lamivudine+adefovir- and entecavir-resistant HBV strains 9 
(Tables 2 and 3). Clinically, tenofovir has been used successfully for the treatment of patients 10 
who successively failed lamivudine and lamivudine+adefovir dipivoxil therapy (16, 23, 24). 11 
Several clinical reports suggested a potent  anti-HBV activity of tenofovir in patients failing 12 
adefovir therapy and moreover a better anti-HBV activity of tenofovir over adefovir in 13 
patients failing lamivudine therapy (13, 21), which may be due to better pharmacokinetic 14 
properties. Whether tenofovir may select for  drug-resistant mutants in patients remains a 15 
matter of controversy (5, 18).  16 
The development of novel strategies for HBV therapy that may be based on the 17 
combination of various nucleoside analogs with different cross-resistant profile will require 18 
the discovery of novel HBV inhibitors. We recently demonstrated the in vitro potency of the 19 
2’, 3’-dideoxy-3’-fluoroguanosine to inhibit wt, lamivudine-, adefovir- and lamivudine + 20 
adefovir-resistant laboratory HBV strains (12). In the present study, we confirmed previous 21 
studies that showed that PMEO-DAPym is a potent inhibitor of wt HBV in vitro (27). 22 
Interestingly, we provide new information showing that PMEO-DAPym inhibits the 23 
replication of lamivudine-, entecavir-, adefovir- and lamivudine+adefovir-resistant mutants 24 
almost as efficiently as that of wt HBV (Tables 2 and 3). The in vitro cross-resistance profile 25 
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of PMEO-DAPym on the laboratory and clinical strains studied here proved to be more 1 
favorable than that of lamivudine, adefovir and entecavir, and was more or less comparable to 2 
that of tenofovir.  3 
Interestingly, PMEO-DAPym efficiently inhibited all HBV variants harbouring the 4 
rtL180M/M204V mutations which is the most frequently observed lamivudine-resistant 5 
mutant in patients (14, 30) (Tables 2 and 3). Until now, only purine analogs, such as adefovir 6 
or tenofovir, have shown activity against the replication of the lamivudine-resistant 7 
rtL180M/M204V mutant which is resistant to lamivudine and all known pyrimidine L-8 
nucleosides (29). Thus, PMEO-DAPym, although not carrying a purine base, exhibits the 9 
same cross-resistance profile as purine-based nucleoside phosphonate analogs. This supports 10 
our earlier assumption that (based on molecular modelling) that the 2,4-diamino-substituted 11 
pyrimidine ring of PMEO-DAPym can be viewed as a open-ring analog of the purine system 12 
in the 2,6-diaminopurine acyclic nucleoside phosponate derivatives (27). Although most 13 
adefovir- and lamivudine+adefovir-resistant HBV strains retained some degree of 14 
susceptibility to adefovir in vitro (Table 2 and 3), its clinical efficacy is limited by its 15 
nephrotoxicity when the daily dose of adefovir dipivoxil is increased from 10 to 30 mg (15). 16 
In our experimental conditions, tenofovir and PMEO-DAPym exhibited the most favourable 17 
in vitro cross-resistance profiles as inhibitors of the replication of multiple drug-resistant 18 
HBV genomes derived from clinical strains from patients who failed sequential therapy with 19 
currently approved HBV inhibitors. Therefore, it will be interesting to determine the 20 
pharmacodynamics of PMEO-DAPym in vivo.  21 
In conclusion, the broad inhibitory activity of PMEO-DAPym against HBV drug-22 
resistant mutants and its favorable cytotoxicity profile, observed in tissue culture experiments, 23 
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Table 1: Activity of PMEO-DAPym and selected compounds against wild-type HBV 3 











 For each drug, the EC50 value is the mean of the EC50 of wild-type HBV that are 14 
shown in Tables 2 and 3.  15 
2











1 ± 1.1 
 
> 1000 
Entecavir 0.3 ± 0.42 125 ± 35 
Adefovir 13 ± 29 365 ± 120 
Tenofovir 16 ± 7.9 > 1000 
PMEO-DAPym 4.9 ± 0.6 > 1000 
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